Covista (CVSA) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barrington Research | Maintained | Outperform | $170.00 | Jun 8, 2026 |
| Truist Securities | Maintained | Buy | $140.00 from $130.00 | May 11, 2026 |
| Barrington Research | Maintained | Outperform | $170.00 | Apr 17, 2026 |
| Truist Securities | Initiated Coverage | Buy | $130.00 | Mar 24, 2026 |
| Barrington Research | Maintained | Outperform | $170.00 | Mar 2, 2026 |
| Barrington Research | Maintained | Outperform | $170.00 | Jan 29, 2026 |
| Barrington Research | Maintained | Outperform | $170.00 | Oct 31, 2025 |
| Barrington Research | Maintained | Outperform | $170.00 from $150.00 | Oct 15, 2025 |
| Barrington Research | Maintained | Outperform | $150.00 | Sep 23, 2025 |
| Barrington Research | Maintained | Outperform | $150.00 from $140.00 | Aug 8, 2025 |
| Barrington Research | Maintained | Outperform | $140.00 | Jul 30, 2025 |
| BMO Capital | Maintained | Outperform | $132.00 from $115.00 | May 12, 2025 |
| Barrington Research | Maintained | Outperform | $140.00 from $120.00 | May 9, 2025 |
| Jefferies | Initiated Coverage | Buy | $135.00 | Apr 23, 2025 |
| Barrington Research | Maintained | Outperform | $120.00 | Apr 15, 2025 |
| BMO Capital | Maintained | Outperform | $115.00 from $108.00 | Feb 3, 2025 |
| Barrington Research | Maintained | Outperform | $120.00 from $115.00 | Jan 31, 2025 |
| Barrington Research | Maintained | Outperform | $115.00 from $95.00 | Jan 17, 2025 |
| Barrington Research | Maintained | Outperform | $95.00 from $90.00 | Oct 30, 2024 |
| BMO Capital | Maintained | Outperform | $90.00 from $84.00 | Oct 30, 2024 |
Frequently asked questions
Is CVSA a buy, sell, or hold?
Analysts covering Covista currently average a Buy rating: 4 buy, 0 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CVSA?
On Jun 8, 2026, Barrington Research maintained Covista at Outperform with a price target of $170.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.